We are not aware of any blood samples from haemophiliacs currently in such use. No samples would be used without ensuring compliance with appropriate ethical and legal processes.
In September 2004 selected groups of patients were informed about the results of a risk assessment exercise for blood plasma products, undertaken by the Health Protection Agency. As part of this exercise, the batch numbers for plasma products implicated with variant Creutzfeldt-Jakob Disease were sent to national health service trusts, primary care trusts and to the United Kingdom Haemophilia Centre Doctors Organisation.